Examination of gynecological cancer cases with metastatic brain tumor in our hospital

DOI
  • Nakamoto Kosuke
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Tomono Katsuyuki
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Uyama Takuto
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Morioka Hirohiko
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Sekine Masaki
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Nosaka Suguru
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Yamazaki Tomomi
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Koh Iemasa
    Department of Obstetrics and Gynecology of Hiroshima University Hospital
  • Kudo Yoshiki
    Department of Obstetrics and Gynecology of Hiroshima University Hospital

Bibliographic Information

Other Title
  • 当院において転移性脳腫瘍を認めた婦人科悪性腫瘍の検討
Published
2024-04-25
DOI
  • 10.57291/jsgo.42.2_182
Publisher
Japan Society of Gynecologic Oncology

Search this article

Description

<p>Synopsis: Brain metastasis has a substantial impact on survival and quality of life. Brain metastasis stemming from gynecological malignancies is rare compared to that from other cancers. In this study, we retrospectively examined the clinical characteristics, treatment for brain metastasis stemming from gynecological malignancies, and prognosis of 14 patients diagnosed and treated at our hospital from January 2008 to December 2020. The primary disease was cervical cancer in three cases, uterine cancer in five, uterine sarcoma in one, and ovarian cancer in five. The brain metastasis was a single brain metastasis in 4 cases and multiple metastases in 10 cases. For patients with a single metastasis, surgery was the treatment of choice, whereas radiation was the treatment of choice for those with multiple metastases. The median survival after diagnosis of brain metastasis was 2.3 months for cervical cancer, 3.7 months for uterine cancer, and 32.5 months for ovarian cancer. The survival time was 27.7 months in the single metastasis group and 3.4 months in the multiple metastases group. Brain metastases generally yield a poor prognosis, but aggressive treatment may be considered because patients may survive for multiple years.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top